Other blood based biomarkers such as human glandular kallikrein 2 (hK2), urokinase plasminogen activator (uPA) and its receptor (uPAR), transforming growth factor-beta 1 (TGF- β1); interleukin-6 (IL-6) and its receptor (IL-6R) have been studied alone or in combination with PSA and suggested for diagnosis, staging, prognostics, and monitoring of prostate cancer [10]. Here, PLAU is linked to prostate carcinoma.